Compare OXSQ & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | NRXP |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 153.2M |
| IPO Year | 2003 | 2017 |
| Metric | OXSQ | NRXP |
|---|---|---|
| Price | $1.35 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | ★ 1.5M | 991.4K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | $3.61 | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | $13.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $1.65 |
| 52 Week High | $2.21 | $5.06 |
| Indicator | OXSQ | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 47.48 |
| Support Level | $1.29 | $3.09 |
| Resistance Level | $1.43 | $3.62 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 32.14 | 58.35 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.